Plerixafor octahydrochloride is supported by numerous clinical trials spanning Early Phase 1 through Phase 4. Research focuses primarily on hematopoietic stem cell mobilization for autologous transplantation in hematologic malignancies—such as multiple myeloma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia—while expanding into non-oncologic indications including skin wound healing, sickle cell disease, and COVID-19 acute respiratory distress syndrome. Sponsored by academic institutions, health services, and pharmaceutical developers, study statuses range from active recruitment and completed pivotal studies to terminated or withdrawn trials.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06851767 | ENROLLING_BY_INVITATION | X-linked Severe Combined Immunodeficiency; X-SCID; XSCID |
National Institute of Allergy and Infectious Diseases (NIAID) |
2025-05-09 | PHASE1; PHASE2 |
| NCT06325709 | RECRUITING | Chronic Granulomatous Disease (CGD); X-Linked Chronic Granulomatous Disease |
National Institute of Allergy and Infectious Diseases (NIAID) |
2024-04-17 | PHASE1; PHASE2 |
| NCT07605416 | RECRUITING | Plasma Cell Leukemia |
National Cancer Institute (NCI) |
2027-04-20 | PHASE2 |
| NCT07775313 | NOT_YET_RECRUITING | WHIM; Warts; Hypogammaglobulinemia; Immunodeficiency; Myelokathexis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2026-09-09 | PHASE1; PHASE2 |
| NCT02015013 | RECRUITING | Idiopathic CD4-Positive; T-Lymphocytopenia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-01-15 | PHASE2 |
| NCT06872333 | RECRUITING | Graft Failure; Sickle Cell Disease; Hemoglobinopathies |
Masonic Cancer Center, University of Minnesota |
2024-11-19 | PHASE2 |
| NCT06207799 | RECRUITING | Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy; Pre-transplant Purging |
M.D. Anderson Cancer Center |
2024-07-17 | PHASE2 |
| NCT06506461 | RECRUITING | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2025-03-21 | PHASE1 |
| NCT07585136 | NOT_YET_RECRUITING | Bone Marrow Failure Syndrome |
St. Jude Children's Research Hospital |
2026-11 | PHASE1 |
| NCT06158828 | RECRUITING | AML, Childhood; Aml; Acute Myeloid Leukemia, Pediatric; Acute Myeloid Leukemia |
Washington University School of Medicine |
2024-11-15 | PHASE1; PHASE2 |
| NCT05088356 | ACTIVE_NOT_RECRUITING | Allogeneic Hematopoietic Cell Transplantation (HCT); Advanced Hematologic Malignancies; Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders |
Stanford University |
2021-09-07 | PHASE1 |
| NCT07188090 | RECRUITING | Multiple Myeloma; Hodgkin Lymphoma; Non-hodgkin Lymphoma |
Thomas Jefferson University |
2025-10-16 | PHASE2 |
| NCT07341022 | NOT_YET_RECRUITING | Sickle Cell Disease |
Hospital Israelita Albert Einstein |
2026-06-01 | PHASE1; PHASE2 |
| NCT05470491 | RECRUITING | HIV; Hematologic Malignancies |
National Cancer Institute (NCI) |
2023-01-26 | PHASE1; PHASE2 |
| NCT03664830 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease |
City of Hope Medical Center |
2018-09-19 | PHASE1 |
| NCT06414889 | RECRUITING | RUNX1 Familial Platelet Disorder |
M.D. Anderson Cancer Center |
2024-05-20 | PHASE1 |
| NCT05343572 | RECRUITING | Asherman Syndrome; Atrophic Endometrium; Recurrent Implantation Failure |
Hugh Taylor |
2023-11-01 | EARLY_PHASE1 |
| NCT02570542 | ACTIVE_NOT_RECRUITING | Diffuse Large B-cell Lymphoma (DLBCL); Relapsed Diffuse Large B-cell Lymphoma (DLBCL); Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
Memorial Sloan Kettering Cancer Center |
2015-10 | PHASE2 |
| NCT04362293 | ACTIVE_NOT_RECRUITING | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2020-04-30 | PHASE2 |
| NCT05357482 | ACTIVE_NOT_RECRUITING | Sickle Cell Anemia; Beta Thalassemia |
National Heart, Lung, and Blood Institute (NHLBI) |
2022-05-12 | PHASE1; PHASE2 |
| NCT03653247 | COMPLETED | Sickle Cell Disease |
Sangamo Therapeutics |
2019-03-06 | PHASE1; PHASE2 |
| NCT02193191 | COMPLETED | Sickle Cell Disease |
Memorial Sloan Kettering Cancer Center |
2014-09-17 | PHASE1 |
| NCT06141304 | UNKNOWN | Relapsed Adult ALL; Relapsed Adult AML |
The First Hospital of Jilin University |
2023-09-01 | PHASE2 |
| NCT01526096 | COMPLETED | Myeloma |
University of Chicago |
2011-07-12 | PHASE1 |
| NCT03182426 | COMPLETED | Diabetes Mellitus, Type 1 |
University of Alberta |
2017-08-15 | PHASE1; PHASE2 |
| NCT05421416 | Not yet recruiting | Stem Cell Transplant Complications |
AHS Cancer Control Alberta |
2024-04-01 | Phase 2 |
| NCT01331018 | TERMINATED | Fanconi Anemia |
Fred Hutchinson Cancer Center |
2012-02-22 | PHASE1 |
| NCT05510544 | UNKNOWN | Lymphoma |
Peking University |
2022-12-19 | PHASE4 |
| NCT05343572 | Recruiting | Asherman Syndrome|Atrophic Endometrium|Recurrent Implantation Failure |
Hugh Taylor|Yale University |
2023-11-01 | Early Phase 1 |
| NCT05844527 | Recruiting | Wound of Skin|Abdominal Wound |
MedRegen LLC |
2023-11-20 | Phase 2 |
| NCT03240861 | TERMINATED | HLA-A*0201 Positive Cells Present; Locally Advanced Malignant Neoplasm; NY-ESO-1 Positive; Unresectable Malignant Neoplasm; Sarcoma |
Jonsson Comprehensive Cancer Center |
2017-07-26 | PHASE1 |
| NCT01413100 | COMPLETED | Systemic Scleroderma |
Fred Hutchinson Cancer Center |
2011-09-15 | PHASE2 |
| NCT03055247 | RECRUITING | Chronic Granulomatous Disease X-linked (X-CGD) |
IRCCS San Raffaele |
2015-11-06 | PHASE2 |
| NCT04817345 | WITHDRAWN | Sickle Cell Disease |
St. Jude Children's Research Hospital |
2023-04 | PHASE2 |
| NCT04177810 | COMPLETED | Metastatic Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2020-11-16 | PHASE2 |
| NCT03547830 | UNKNOWN | Chronic Granulomatous Disease |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2019-04-13 | PHASE2 |
| NCT05445128 | TERMINATED | Sickle Cell Disease |
Ensoma |
2022-06-24 | PHASE2 |
| NCT05087212 | COMPLETED | Autologous Haematopoietic Stem Cell Transplant |
Sanofi |
2021-10-22 | PHASE4 |
| NCT05007652 | COMPLETED | Multiple Myeloma and Malignant Lymphoma |
Kyowa Kirin Co., Ltd. |
2021-09-01 | PHASE2 |
| NCT05411575 | WITHDRAWN | COVID-19 Acute Respiratory Distress Syndrome; COVID-19 |
4Living Biotech |
2022-07-19 | PHASE2 |
| NCT05411575 | Withdrawn | COVID-19 Acute Respiratory Distress Syndrome|COVID-19 |
4Living Biotech|4P-Pharma |
2022-07-19 | Phase 2 |
| NCT05445128 | Terminated | Sickle Cell Disease |
Ensoma|bluebird bio |
2022-06-24 | Phase 2 |
| NCT03746080 | COMPLETED | Glioblastoma; Glioblastoma With Primitive Neuronal Component; Gliosarcoma; Malignant Glioma; Oligodendroglial Component Present |
Lawrence D Recht |
2018-12-04 | PHASE2 |
| NCT05835726 | Recruiting | Multiple Myeloma|Daratumumab|Autologous Stem Cell Transplantation|Leukapheresis |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2022-01-01 | -- |
| NCT04762875 | TERMINATED | Related Donors Donating PBSC to a Family Member; Healthy Donors; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome |
Ensoma |
2021-06-16 | PHASE2 |
| NCT04552743 | COMPLETED | Multiple Myeloma |
Surbhi Sidana, MD |
2020-10-05 | PHASE2 |
| NCT03317899 | COMPLETED | Non-Hodgkin's Lymphoma; Plasma Cell Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2017-10-12 | PHASE2 |
| NCT04045821 | TERMINATED | Infertility of Uterine Origin |
Reproductive Medicine Associates of New Jersey |
2020-01-17 | |
| NCT06892119 | COMPLETED | Lymphoma; Myeloma |
Hospital Universitario Dr. Jose E. Gonzalez |
2019-12-09 | PHASE1 |
| NCT02231879 | COMPLETED | Myelokathexis; Infections; Neutropenia; Warts; Hypogammaglobulinemia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-10-14 | PHASE2; PHASE3 |
| NCT02522572 | UNKNOWN | Transplants and Implants |
E. Steve Woodle |
2015-08 | PHASE1; PHASE2 |
| NCT02343666 | WITHDRAWN | Human Immunodeficiency Virus 1 Positive; Stage I Adult Hodgkin Lymphoma; Stage I Adult Non-Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult Non-Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Non-Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2016-08-15 | PHASE1 |
| NCT03932864 | COMPLETED | Healthy Volunteers |
Ensoma |
2019-04-22 | PHASE1 |
| NCT03277209 | TERMINATED | Pancreas Cancer |
Weill Medical College of Cornell University |
2017-07-25 | PHASE1 |
| NCT04058145 | WITHDRAWN | Head and Neck Cancer |
Massachusetts General Hospital |
2019-09-30 | PHASE2 |
| NCT02790957 | TERMINATED | Diabetes; Wounds; Critical Limb Ischemia |
Gian Paolo Fadini |
2016-06 | PHASE2 |
| NCT03506802 | WITHDRAWN | HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Jonsson Comprehensive Cancer Center |
2018-07-10 | PHASE1 |
| NCT03157804 | COMPLETED | Fanconi Anemia |
Hospital Infantil Universitario Niño Jesús, Madrid, Spain |
2016-01-07 | PHASE1; PHASE2 |
| NCT03226691 | COMPLETED | Sickle Cell Disease |
National Heart, Lung, and Blood Institute (NHLBI) |
2017-07-25 | PHASE1 |
| NCT01146834 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2011-03 | PHASE3 |
| NCT02006225 | UNKNOWN | Autologous Stem Cell Transplantation |
Tel-Aviv Sourasky Medical Center |
2014-02 | PHASE4 |
| NCT02179970 | COMPLETED | Pancreatic Adenocarcinoma Metastatic; Ovarian Serous Adenocarcinoma; Colorectal Cancer Metastatic |
CCTU- Cancer Theme |
2015-06 | PHASE1 |
| NCT03019809 | UNKNOWN | Wiskott-Aldrich Syndrome; Hematopoietic Stem Cell Transplantation; Graft Failure |
Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
2016-06 | PHASE2 |
| NCT02678533 | COMPLETED | Fanconi Anemia |
Assistance Publique - Hôpitaux de Paris |
2017-02-10 | PHASE1; PHASE2 |
| NCT02931071 | COMPLETED | Fanconi Anemia |
Hospital Universitari Vall d'Hebron Research Institute |
2013-09 | PHASE2 |
| NCT02069080 | TERMINATED | Cancer |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-02-20 | EARLY_PHASE1 |
| NCT00669669 | TERMINATED | Glioblastoma; Gliosarcoma |
Fred Hutchinson Cancer Center |
2009-02-25 | PHASE1; PHASE2 |
| NCT03244930 | UNKNOWN | Lymphoma, Non-Hodgkin; Lymphoma, Hodgkin; Myeloma; Stem Cell Transplant Complications |
Hospital Universitario Dr. Jose E. Gonzalez |
2017-05-10 | PHASE2 |
| NCT02989701 | COMPLETED | Sickle Cell Disease Without Crisis |
Alessandra Biffi |
2017-01 | PHASE1 |
| NCT01977677 | COMPLETED | Adult Ependymoblastoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Medulloblastoma; Adult Mixed Glioma; Adult Oligodendroglial Tumors; Adult Pineoblastoma; Adult Supratentorial Primitive Neuroectodermal Tumor (PNET) |
Lawrence Recht |
2014-11 | PHASE1; PHASE2 |
| NCT01916577 | COMPLETED | COPD; Cystic Fibrosis; Pulmonary Fibrosis |
University of Colorado, Denver |
2013-08 | PHASE1 |
| NCT01288573 | COMPLETED | Ewing's Sarcoma/Soft Tissue Sarcoma; Neuroblastoma; Brain Tumors |
Genzyme, a Sanofi Company |
2014-03-03 | PHASE1; PHASE2 |
| NCT02212535 | COMPLETED | Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia |
Assistance Publique - Hôpitaux de Paris |
2016-01-15 | PHASE1; PHASE2 |
| NCT00943943 | COMPLETED | Acute Myelogenous Leukemia; Leukemia |
M.D. Anderson Cancer Center |
2010-10-29 | PHASE1 |
| NCT02682953 | WITHDRAWN | Bone Marrow Transplantation; Hematopoietic Stem Cells; Multiple Myeloma; Lymphoma |
University of Maryland, Baltimore |
2015-10 | PHASE2 |
| NCT01352650 | COMPLETED | Acute Myeloid Leukemia |
Weill Medical College of Cornell University |
2011-06-17 | PHASE1 |
| NCT01753453 | COMPLETED | Multiple Myeloma |
Sanofi |
2013-06 | PHASE2 |
| NCT01696461 | COMPLETED | Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member; Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia; Non-Hodgkin's Lymphoma; Hodgkin's Disease; Chronic Lymphocytic Leukemia |
Center for International Blood and Marrow Transplant Research |
2013-05 | PHASE2 |
| NCT02098109 | COMPLETED | Multiple Myeloma; Lymphoma, Non-Hodgkin |
Washington University School of Medicine |
2014-08-20 | PHASE2 |
| NCT01818284 | COMPLETED | Blood And Marrow Transplantation |
M.D. Anderson Cancer Center |
2013-10 | PHASE2 |
| NCT00903968 | COMPLETED | Multiple Myeloma |
Dana-Farber Cancer Institute |
2009-06-01 | PHASE1; PHASE2 |
| NCT01435343 | COMPLETED | Acute Myeloblastic Leukemia |
PETHEMA Foundation |
2012-07 | PHASE1; PHASE2 |
| NCT01408043 | TERMINATED | Adult Acute Lymphoblastic Leukemia in Remission; Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenström Macroglobulinemia |
Case Comprehensive Cancer Center |
2011-10 | |
| NCT02221492 | COMPLETED | Lymphoma |
Genzyme, a Sanofi Company |
2014-11 | PHASE2 |
| NCT02200380 | TERMINATED | For Donors; Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling; For Recipients; Acute Myelogenous Leukemia (AML); Acute Lymphoblastic Leukemia (ALL); Myelodysplastic Syndrome (MDS); Chronic Myelogenous Leukemia (CML); Non-Hodgkins Lymphoma (NHL); Hodgkins Disease (HD); Chronic Lymphocytic Leukemia (CLL) |
Celldex Therapeutics |
2014-07 | PHASE2 |
| NCT01160354 | TERMINATED | Acute Myelogenous Leukemia |
M.D. Anderson Cancer Center |
2010-08 | PHASE1; PHASE2 |
| NCT01353937 | WITHDRAWN | Diabetic Ulcer |
NYU Langone Health |
2014-04 | PHASE1 |
| NCT01954914 | COMPLETED | Blood Stem Cell Harvest Failure |
Technische Universität Dresden |
2013-12 | PHASE2 |
| NCT01621477 | TERMINATED | Acute Lymphoblastic Leukemia; Acute Myelocytic Leukemia; Chronic Myelocytic Leukemia; Juvenile Myelomonocytic Leukemia; Myelodysplastic Syndrome; Hodgkin or Non-Hodgkin Lymphoma; Sarcoma, Myeloid |
St. Jude Children's Research Hospital |
2012-08 | PHASE2 |
| NCT01403896 | COMPLETED | Malignant Lymphoma, Stem Cell Type |
Stephen Couban |
2012-04 | PHASE2 |
| NCT01339572 | COMPLETED | Non-Hodgkin's Lymphoma; Multiple Myeloma |
University of Florida |
2011-04 | PHASE2 |
| NCT02221479 | COMPLETED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2014-10 | PHASE2 |
| NCT01186224 | COMPLETED | Multiple Myeloma; Plasma Cell Dyscrasia; Lymphoma; Lymphoproliferative Disorders |
University of Liverpool |
2010-05 | |
| NCT01164345 | COMPLETED | Non-Hodgkin's Lymphoma; Hodgkin's Lymphoma; Stem Cell Mobilization; Autologous Stem Cell Transplantation |
Sheba Medical Center |
2010-06 | PHASE2 |
| NCT01455025 | TERMINATED | Acute Myeloid Leukemia |
French Innovative Leukemia Organisation |
2012-01 | PHASE1 |
| NCT00322127 | COMPLETED | Healthy Volunteers |
National Heart, Lung, and Blood Institute (NHLBI) |
2006-06-14 | PHASE1 |
| NCT01767714 | COMPLETED | Non-Hodgkin's Lymphoma |
Sanofi |
2013-04 | PHASE3 |
| NCT01746173 | TERMINATED | T-cell Non-Hodgkin Lymphoma |
Dana-Farber Cancer Institute |
2013-07 | PHASE2 |
| NCT02056210 | COMPLETED | Diabetes |
University of Padova |
2014-02 | PHASE4 |
| NCT01280955 | COMPLETED | Failure of Bone Marrow Graft |
Mitchell Horwitz, MD |
2011-12 | PHASE1; PHASE2 |
| NCT01065129 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2010-09-02 | PHASE1 |
| NCT01547806 | COMPLETED | Plasma Cell Myeloma; Multiple Myeloma |
National Cancer Institute (NCI) |
2012-02-22 | PHASE2 |
| NCT01610999 | TERMINATED | Chronic Lymphocytic Leukemia; Lymphoma; Multiple Myeloma |
Tufts Medical Center |
2013-07 | PHASE1 |
| NCT01026987 | COMPLETED | Stem Cell Transplant Patients |
Washington University School of Medicine |
2010-04-29 | PHASE1 |
| NCT01339039 | TERMINATED | High Grade Glioma: Glioblastoma (GBM); High Grade Glioma: Gliosarcoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Mixed Anaplastic Oligoastrocytoma (AOA) |
Patrick Y. Wen, MD |
2011-12 | PHASE1 |
| NCT01655875 | TERMINATED | Pediatric Acute Myeloblastic Leukemia, Relapsed; Pediatric Acute Lymphoblastic Leukemia, Relapsed |
Emory University |
2012-06 | PHASE1 |
| NCT01373229 | COMPLETED | Leukemia, Lymphocytic, Chronic, B-Cell |
David Rizzieri, MD |
2012-01 | PHASE1 |
| NCT01158118 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple Myeloma |
Washington University School of Medicine |
2011-04-01 | PHASE2 |
| NCT01236144 | COMPLETED | Acute Myeloid Leukaemia; High Risk Myelodysplastic Syndrome |
Cardiff University |
2011-04 | PHASE1; PHASE2 |
| NCT01318317 | ACTIVE_NOT_RECRUITING | Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma |
City of Hope Medical Center |
2011-09-19 | PHASE1; PHASE2 |
| NCT01068301 | COMPLETED | Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma |
St. Jude Children's Research Hospital |
2010-05 | PHASE1 |
| NCT01182675 | TERMINATED | Severe Combined Immunodeficiency |
University of California, San Francisco |
2010-08 | PHASE2 |
| NCT01097057 | COMPLETED | Non-Hodgkin Lymphoma |
Fred Hutchinson Cancer Center |
2010-11-09 | PHASE2 |
| NCT01037517 | COMPLETED | Multiple Myeloma; Lymphoma |
CancerCare Manitoba |
2010-01 | PHASE2 |
| NCT01319864 | COMPLETED | Relapsed/Refractory AML; Relapsed/Refractory ALL; Secondary AML/MDS; Acute Leukemia of Ambiguous Lineage; AML; ALL |
Seattle Children's Hospital |
2011-03 | PHASE1 |
| NCT01301963 | TERMINATED | Refractory Multiple Myeloma |
Case Comprehensive Cancer Center |
2011-07 | PHASE3 |
| NCT01802892 | COMPLETED | Transplantation, Stem Cell |
GlaxoSmithKline |
2012-11-02 | PHASE1 |
| NCT01164475 | COMPLETED | Non-Hodgkin's Lymphoma |
Genzyme, a Sanofi Company |
2010-10 | PHASE4 |
| NCT01074060 | COMPLETED | Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
City of Hope Medical Center |
2010-04 | PHASE1 |
| NCT00906945 | COMPLETED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2011-02 | PHASE1; PHASE2 |
| NCT00082329 | COMPLETED | Healthy |
National Heart, Lung, and Blood Institute (NHLBI) |
2004-06-18 | PHASE2 |
| NCT00822770 | COMPLETED | Stem Cell Transplantation; Leukemia |
M.D. Anderson Cancer Center |
2009-01 | PHASE1; PHASE2 |
| NCT00733824 | COMPLETED | Lymphoma, Non-Hodgkin; Hodgkin Disease |
Washington University School of Medicine |
2008-11 | PHASE1; PHASE2 |
| NCT00075335 | COMPLETED | Healthy |
National Heart, Lung, and Blood Institute (NHLBI) |
2004-01 | PHASE2 |
| NCT01095757 | COMPLETED | Myeloma; Lymphoma |
Emory University |
2010-03 | PHASE2 |
| NCT00990054 | COMPLETED | Acute Myeloid Leukemia |
Genzyme, a Sanofi Company |
2009-12 | PHASE1 |
| NCT01579149 | COMPLETED | Healthy Volunteer |
Genzyme, a Sanofi Company |
2011-09 | PHASE1 |
| NCT01220375 | COMPLETED | Myeloma |
Insel Gruppe AG, University Hospital Bern |
2010-04 | PHASE2 |
| NCT01149863 | COMPLETED | Autologous Transplantation |
Emory University |
2010-06 | PHASE2 |
| NCT01042717 | UNKNOWN | Multiple Myeloma; Non-Hodgkins Lymphoma |
Shi, Patricia, M.D. |
2010-02 | |
| NCT00998049 | COMPLETED | Multiple Myeloma; Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
Mayo Clinic |
2009-12 | PHASE2 |
| NCT01225419 | COMPLETED | Children Cancer, Solid Tumor |
University Hospital, Clermont-Ferrand |
2010-09 | PHASE2 |
| NCT01058993 | COMPLETED | Neutropenia |
University of Washington |
2010-10 | PHASE1 |
| NCT01076270 | TERMINATED | Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma |
Fred Hutchinson Cancer Center |
2010-06 | |
| NCT00914849 | COMPLETED | Hematologic Neoplasms |
Washington University School of Medicine |
2009-08 | PHASE2 |
| NCT00479115 | COMPLETED | Fanconi Anemia |
Children's Hospital Medical Center, Cincinnati |
2007-05 | PHASE1; PHASE2 |
| NCT00694590 | COMPLETED | Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Genzyme, a Sanofi Company |
2008-06 | PHASE1 |
| NCT00838357 | COMPLETED | Lymphoma (Non-Hodgkin's Lymphoma); Hodgkin's Disease or Multiple Myeloma; Front Line Mobilization; Transplantation |
Genzyme, a Sanofi Company |
2008-09 | PHASE3 |
| NCT00901225 | COMPLETED | Multiple Myeloma; Non-Hodgkins Lymphoma; Hodgkins Disease |
Duke University |
2009-05 | PHASE2 |
| NCT01027923 | TERMINATED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2010-05 | PHASE1 |
| NCT00512252 | COMPLETED | Leukemia, Myeloid, Acute |
Washington University School of Medicine |
2007-07 | PHASE1; PHASE2 |
| NCT00396331 | COMPLETED | Autologous Stem Cell Transplantation |
Genzyme, a Sanofi Company |
2005-10 | PHASE2 |
| NCT00241358 | COMPLETED | Leukemia, Myeloid, Acute; Leukemia, Myelogenous, Chronic; Leukemia, Lymphoblastic, Acute; Lymphocytic Leukemia, Chronic; Myelodysplastic Syndromes; Multiple Myeloma; Lymphoma, Non-Hodgkin; Hodgkin Disease |
Washington University School of Medicine |
2004-05 | PHASE1; PHASE2 |
| NCT00444912 | COMPLETED | Non-Hodgkin Lymphoma; Hodgkin Disease |
Genzyme, a Sanofi Company |
2006-02 | PHASE2 |
| NCT00665314 | COMPLETED | Lymphoma; Non Hodgkin's Lymphoma; Hodgkin's Disease; Multiple Myeloma |
Genzyme, a Sanofi Company |
2007-11 | PHASE2 |
| NCT00396266 | COMPLETED | Multiple Myeloma; Lymphoma, Non-Hodgkin |
Genzyme, a Sanofi Company |
2005-01 | PHASE2 |
| NCT00445302 | COMPLETED | Renal Impairment |
Genzyme, a Sanofi Company |
2006-01 | PHASE1 |
| NCT00396383 | TERMINATED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-11 | PHASE2 |
| NCT00322842 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-09 | PHASE2 |
| NCT00396201 | COMPLETED | Hodgkin's Disease |
Genzyme, a Sanofi Company |
2004-11 | PHASE2 |
| NCT00103662 | COMPLETED | Multiple Myeloma |
Genzyme, a Sanofi Company |
2005-01 | PHASE3 |
| NCT00103610 | COMPLETED | Lymphoma, Non-Hodgkin |
Genzyme, a Sanofi Company |
2005-01 | PHASE3 |
| NCT00322387 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-04 | PHASE2 |
| NCT00322491 | COMPLETED | Lymphoma, Non-Hodgkin; Multiple Myeloma |
Genzyme, a Sanofi Company |
2004-03 | PHASE2 |
| NCT00395967 | TERMINATED | Multiple Myeloma; Lymphoma, Non-Hodgkin's |
Genzyme, a Sanofi Company |
2005-04 | PHASE2 |
| NCT00396968 | WITHDRAWN | Acute Myelogenous Leukemia; Myelodysplastic Syndromes |
Genzyme, a Sanofi Company |
PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-09-03)
Check the
Plerixafor (AMD3100) 8HCl
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Plerixafor (AMD3100) 8HCl Solubility in DMSO
- Plerixafor (AMD3100) 8HCl Stock Solution
- Plerixafor (AMD3100) 8HCl Storage
- Plerixafor (AMD3100) 8HCl Stability
- Plerixafor (AMD3100) 8HCl Molecular Weight
- Plerixafor (AMD3100) 8HCl SMILES
- Plerixafor (AMD3100) 8HCl CAS Number
- Plerixafor (AMD3100) 8HCl Chemical Structure (2D and 3D)
- Plerixafor (AMD3100) 8HCl SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.